iBio Inc.

iBio widened its net loss to $33.0 million for the fiscal year ended June 30, 2026, on revenues of about $0.1 million. R&D expenses rose to $19.6 million, including higher consulting and CMC costs, and a $5.0 million impairment on IBIO-101 was recorded. Cash and short-term investments amounted to approximately $88.0 million after capital raises via a public offering in 2025 and a private placement in early 2026. The company reported clinical progress for IBIO-600 (31 of 32 participants in the single-dose part without safety concerns), for IBIO-610, and for the development transition of IBIO-800 into IND-relevant studies. Molly Carr was appointed chief medical officer and Elizabeth Stoner was named to the board. » Plus sur de.investing.com

iBio has appointed Dr. Elizabeth Stoner as an independent member of the board of directors and of the compensation committee; she replaces Eef Schimmelpennink. Stoner brings more than 35 years of research and development experience, most recently as Entrepreneur Partner at MPM BioImpact and previously in senior roles at Semma Therapeutics, Rhythm Pharmaceuticals and Merck Research Laboratories. iBio is preparing its first clinical study in humans; the pipeline includes candidates IBIO-610 and IBIO-600 for obesity and pulmonary hypertension, and according to InvestingPro the balance sheet shows more cash than debt. An InvestingPro analysis rates the stock as undervalued at current levels; market capitalization is $59 million. » Plus sur de.investing.com

The Australian drug regulator TGA and an ethics committee have approved iBio’s first clinical phase‑1 trial of the monoclonal antibody IBIO-600; the randomized, double‑blind, placebo‑controlled single‑ascending‑dose study will assess safety, tolerability, pharmacokinetics and pharmacodynamics in overweight and obese adults. iBio plans to administer the first dose in Q2 2026. IBIO-600 targets myostatin and GDF11, is intended to preserve lean mass and could be used alongside GLP‑1 therapies; preclinically the drug showed a half‑life of 40–52 days and a dose‑dependent increase in lean mass. The company has a market capitalization of USD 72.89 million but recorded high cash outflows over the past twelve months and a negative EBITDA of USD 24.7 million. » Plus sur de.investing.com

Ibio raised about $26 million in a private placement led by Frazier Life Sciences by selling 11,061,738 common shares at $2.35 each; closing is expected on January 13, 2026. The proceeds are intended to advance the preclinical cardiometabolic programs IBIO-610 and IBIO-600, as well as bispecific programs targeting myostatin and activin A, and to extend the company’s cash runway to 2028. Institutional healthcare investors participated, Leerink Partners acted as lead placement agent, and there is an option for pre-funded warrants at $2.349 per warrant. » Plus sur de.investing.com

At iBio’s annual general meeting all four proposals were approved: Dr. Martin Brenner and Dr. Alexandra Kropotova were elected as directors (class II) through 2028; Grassi & Co., CPAs, P.C. was confirmed as the independent auditor for the fiscal year ending June 30, 2026; and the named executive compensation was approved in a non-binding vote. Shareholders also decided to hold future advisory votes on executive compensation annually. Additionally, analysts noted that Brookline lowered its price target to $1.60 after a capital raise, while Oppenheimer rates iBio “Outperform” with a $5.00 target and cited expectations for product candidates IBIO-600 and IBIO-610. » Plus sur de.investing.com